Application of cinnamyl aldehyde in preparation of medicine for improving iron-deficiency anemia and adverse pregnancy outcome of pregnant women during pregnancy

Abstract

The invention discloses application of cinnamyl aldehyde in preparation of a medicine for improving iron-deficiency anemia and adverse pregnancy outcome of pregnant women during pregnancy, after the cinnamyl aldehyde is used for treatment, anemia symptoms caused by iron deficiency of pregnant women during pregnancy can be remarkably relieved, adverse pregnancy outcome caused by iron-deficiency anemia can be relieved, and particularly, fetal growth limitation is relieved; and new medicines and treatment choices are provided for clinically treating iron-deficiency anemia of pregnant women during pregnancy and improving adverse pregnancy outcome.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to application of cinnamaldehyde in preparing a medicine for improving iron deficiency anemia and adverse pregnancy outcomes in pregnant women. Background Art

[0002] Clinically, iron deficiency anemia during pregnancy is the most common type of anemia during pregnancy, and is more common in the second and third trimesters of pregnancy. During pregnancy, the demand for iron in pregnant women gradually increases with the pregnancy. Therefore, in the late pregnancy, pregnant women may have insufficient iron intake due to increased demand, malabsorption or lack of food sources, which may lead to iron deficiency anemia. Iron deficiency anemia during pregnancy mainly affects fetal development, including fetal growth restriction (FGR), intrauterine fetal death or premature birth. During pregnancy, the nutrients needed for intrauterine fetal development come from the mother, and various nutrients are transported to the placenta through the blood circulation, and further delivered to the fetus through the umbilical cord connected to the placenta.

[0003] The inventor's research team collected the blood routine results and delivery conditions (growth and development indicators of the newborn on the day of birth) of 250 pregnant women aged 20 to 40 years old from the Third Affiliated Hospital of Southern Medical University from January 2023 to December 2024, and conducted relevant clinical regression analysis and statistical analysis. Clinical regression analysis showed that among the 250 pregnant women aged 20 to 40 years old, about 37.04% of the pregnant women had iron deficiency anemia ( Figure 1 , which has excluded anemia caused by thalassemia). Then, according to clinical data, 250 pregnant women were divided into healthy pregnant women (150 cases) and pregnant women with iron deficiency anemia (100 cases). Statistical analysis showed that compared with healthy pregnant women, pregnant women with iron deficiency anemia had abnormal blood routine test results, specifically, the total red blood cell volume, hemoglobin concentration, hematocrit, mean red blood cell volume, mean hemoglobin and mean hemoglobin concentration were significantly reduced; in addition, pregnant women with iron deficiency anemia had adverse pregnancy outcomes (fetal growth restriction), specifically, decreased biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).

[0004] In addition, older pregnant women (pregnant women aged 35 or above) are more likely to have iron deficiency anemia than pregnant women of normal age because their body conditions begin to decline. Currently, iron deficiency anemia in pregnant women is generally treated clinically by supplementing iron, such as ferrous sulfate or ferrous succinate, ferrous fumarate and ferric citrate. However, these iron supplements have varying degrees of irritation to the gastrointestinal tract, causing pregnant women to experience some adverse symptoms such as upper abdominal discomfort, diarrhea, constipation, etc.

[0005] The Chinese medicine cinnamon is the dried bark of the cinnamon plant of the Lauraceae family. It has the effects of replenishing fire and yang, guiding fire back to the origin, dispelling cold and relieving pain, and warming the meridians and unblocking blood vessels. Cinnamaldehyde is a natural organic matter extracted from the bark of cinnamon. It has multiple biological activities and can regulate the concentration in the body through the intestinal mucosal system. It is not affected by gastric acid in the digestive tract, so it is not destroyed when taken orally, and does not increase the intestinal burden of pregnant women. It has a high biosafety factor. At present, studies have confirmed that cinnamaldehyde plays an important role in antibacterial, anti-inflammatory, anti-ulcer, antioxidant, anti-tumor and fat decomposition. In addition, cinnamaldehyde can improve insulin sensitivity and help lower blood sugar levels, so it has certain clinical significance for pregnant women with gestational diabetes. Cinnamaldehyde contained in cinnamon has the effect of promoting blood circulation. Even so, as one of the important pharmaceutical raw materials, the role of cinnamaldehyde in improving and alleviating iron deficiency anemia in pregnant women during pregnancy is still unclear.

[0006] Currently, there is still a lack of clinical drugs that have no side effects on pregnant women and do not affect the health of mothers and infants to improve iron deficiency anemia during pregnancy. More importantly, research on the treatment of adverse pregnancy outcomes caused by iron deficiency anemia during pregnancy is still in its infancy. Therefore, it is of great significance to develop a drug that can improve iron deficiency anemia during pregnancy and improve adverse pregnancy outcomes. Summary of the invention

[0007] In order to overcome the above defects and shortcomings in the prior art, the present invention provides the use of cinnamaldehyde in the preparation of a drug for improving iron deficiency anemia and adverse pregnancy outcomes in pregnant women.

[0008] The first object of the present invention is to provide the use of cinnamaldehyde in preparing a medicine for improving anemia in pregnant women.

[0009] The second object of the present invention is to provide the use of cinnamaldehyde in preparing a medicine for improving adverse pregnancy outcomes in pregnant women.

[0010] The third object of the present invention is to provide the use of cinnamaldehyde in preparing a medicament for alleviating fetal growth restriction.

[0011] Therefore, the present invention claims the following: Application of cinnamaldehyde in the preparation of medicines for improving anemia in pregnant women.

[0012] Preferably, the anemia is iron deficiency anemia.

[0013] Application of cinnamaldehyde in the preparation of drugs for improving adverse pregnancy outcomes in pregnant women.

[0014] Preferably, the pregnant woman is a pregnant woman suffering from iron deficiency anemia during pregnancy.

[0015] Preferably, the adverse pregnancy outcome of the pregnant woman is an adverse pregnancy outcome caused by iron deficiency anemia of the pregnant woman.

[0016] Further preferably, the adverse pregnancy outcome of the pregnant woman is an adverse pregnancy outcome caused by iron deficiency anemia of the pregnant woman.

[0017] Preferably, the adverse pregnancy outcome is an adverse pregnancy outcome of the fetus.

[0018] Further preferably, the adverse pregnancy outcome is fetal growth restriction.

[0019] More preferably, the fetal growth restriction is fetal growth restriction caused by decreased fetal weight, shortened fetal length and / or decreased placental weight.

[0020] Application of cinnamaldehyde in the preparation of drugs for alleviating fetal growth restriction.

[0021] Preferably, the fetal growth restriction is fetal growth restriction caused by decreased fetal weight, shortened fetal length and / or decreased placental weight.

[0022] Compared with the prior art, the present invention has the following beneficial effects: The invention discloses the use of cinnamaldehyde in the preparation of a drug for improving iron deficiency anemia and adverse pregnancy outcomes during pregnancy. After treatment with cinnamaldehyde, the anemia symptoms caused by iron deficiency during pregnancy can be significantly alleviated. At the same time, the adverse pregnancy outcomes caused by iron deficiency anemia in pregnant women can be alleviated, specifically by alleviating fetal growth restriction, and new drugs and treatment options are provided for the clinical treatment of iron deficiency anemia and adverse pregnancy outcomes in pregnant women. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 These are the clinical data statistics of healthy pregnant women and pregnant women with iron deficiency anemia.

[0024] Figure 2 Schematic diagram of the experimental design for the mouse model.

[0025] Figure 3 These are the anemia indicators of pregnant mice in the normal group (healthy pregnancy group), iron deficiency group (iron deficiency group) and experimental group (iron deficiency + cinnamaldehyde treatment) at gestational day 18.5 (E18.5).

[0026] Figure 4Representative images of the fetuses and placentas in the normal group (healthy pregnancy group), iron deficiency group (iron deficiency group), and experimental group (iron deficiency + cinnamaldehyde treatment group).

[0027] Figure 5 These are the fetal growth and development indicators of the normal group (healthy pregnancy group), iron deficiency group (iron deficiency group) and experimental group (iron deficiency + cinnamaldehyde treatment group). DETAILED DESCRIPTION

[0028] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0029] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0030] Example 1 Construction of a model of iron deficiency anemia in pregnant mice Experimental design flow chart Figure 2 As shown, the mice were divided into normal group, iron-deficient group and experimental group: Normal group: The day when the vaginal plug was found in female mice aged 8 to 12 weeks was recorded as E0.5. They were fed breeding feed (source: Guangdong Medical Experimental Animal Center; iron dosage: 200 ppm) from E0.5, and were allowed to freely consume mouse food. They drank double distilled water without cinnamaldehyde throughout pregnancy, and blood was collected from pregnant mice at E18.5 to test anemia indicators. The pregnant mice were then euthanized and the fetus and placenta were removed.

[0031] Iron-deficient group (Low-iron diet): The day when the vaginal plug was found in female mice aged 8-12 weeks was recorded as E0.5, and they were fed low-iron feed (source: Guangdong Medical Experimental Animal Center; item number: AIN-93G-0Fe iron-deficient purified mouse feed; iron dosage: 2 ppm) from E0.5. They were allowed to freely consume mouse feed and drink double distilled water without cinnamaldehyde throughout pregnancy. Blood was collected from pregnant mice at E18.5 to test anemia indicators. The pregnant mice were then euthanized and the fetus and placenta were removed.

[0032] Experimental group (Cinnamaldehyde): The day when the vaginal plug was found in female mice aged 8 to 12 weeks was recorded as E0.5, and they were fed low-iron feed (source: Guangdong Medical Experimental Animal Center; item number: AIN-93G-0Fe iron-deficient purified mouse feed; iron dosage: 2 ppm; the literature recommends iron content of pregnant mouse feed during pregnancy: 200 ppm) from E0.5, and they were free to take mouse feed. From E13.5, they drank double distilled water containing cinnamaldehyde (Cinnamaldehyde; source: Chengdu Aifa Biotechnology Co., Ltd.; item number: AB2387-0020; CAS number: 104-55-2) every day (cinnamaldehyde was first dissolved in DMSO with a volume fraction of 0.5%), and the dosage was 20 mg / kg / day. Blood was collected from pregnant mice at E18.5 to detect anemia indicators. The pregnant mice were then euthanized and the fetus and placenta were removed.

[0033] Example 2 Effect of cinnamaldehyde on iron deficiency anemia in pregnant mice 1. Experimental Methods The anemia indicators of pregnant mice in the normal group, iron deficiency group and experimental group at gestational day 18.5 (E18.5) in Example 1 were detected. The anemia indicators included total red blood cell (RBC), hemoglobin concentration (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean hemoglobin (MCH) and mean hemoglobin concentration (MCHC).

[0034] 2. Experimental Results The results are as follows Figure 3 The analysis results showed that the total amount of RBC in the blood of normal pregnant mice was 8.0-10.2×10 12 / L, Hb concentration is 125-150 g / L, HCT ratio is 0.4-0.45, MCV is 50-58 fL, MCH is 325-335 pg, and MCHC is 15.8-17.5 g / L.

[0035] Compared with the normal group, the blood parameters of pregnant mice in the iron deficiency group were abnormal, including decreased RBC, Hb, HCT, MCV, MCH and MCHC, among which the total RBC was 6.0-6.2×10 12 / L, Hb concentration 90-108 g / L, HCT ratio 0.28-0.35, MCV 44-48 fL, MCH 280-315 pg, and MCHC 14.5-15.5 g / L.

[0036] Compared with the iron-deficient group, the blood parameters of pregnant mice in the experimental group recovered, specifically, RBC, Hb, HCT, MCV, MCH and MCHC increased, among which the total RBC was 8.0-9.8×10 12 / L, Hb concentration was 120-148 g / L, HCT ratio was 0.42-0.44, MCV was 47-54 fL, MCH was 320-340 pg, and MCHC was 15.5-17.2 g / L, basically restored to the normal group level.

[0037] Example 3 Effect of cinnamaldehyde on fetal growth and development 1. Experimental Methods For the pregnant mice in the normal group, iron deficiency group and experimental group in Example 1, the pregnant mice were euthanized at E18.5 and the fetuses were removed to detect the fetal growth and development indicators: fetal weight, placenta weight, fetal body length and fetal tail length.

[0038] 2. Experimental Results The results are as follows Figure 4 and Figure 5 The analysis results showed that the fetal weight of normal pregnant mice was 0.852-0.122 g, the placenta weight was 0.085-0.123 g, the fetal body length was 19.8-23.2 mm, and the fetal tail length was 10.0-13.2 mm.

[0039] Compared with the normal group, pregnant mice in the iron-deficiency group experienced fetal growth restriction, which was manifested by reduced fetal weight, placental weight, body length and tail length. The fetal weight was 0.683-1.002 g, the placental weight was 0.075-0.118 g, the fetal body length was 17.0-22.5 mm, and the fetal tail length was 8.30-11.7 mm.

[0040] Compared with the iron-deficient group, the pregnant mice in the experimental group recovered fetal growth and development, as manifested by an increase in fetal weight, placental weight, body length and tail length. The fetal weight was 0.950-1.189 g, the placental weight was 0.092-0.121 g, the fetal body length was 21.5-23.3 mm, and the fetal tail length was 10.2-12.8 mm, basically returning to the level of the normal group.

[0041] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Application of cinnamaldehyde in the preparation of drugs for improving anemia in pregnant women.

2. The use according to claim 1, characterized in that: The anemia is iron deficiency anemia.

3. Application of cinnamaldehyde in the preparation of drugs for improving adverse pregnancy outcomes in pregnant women.

4. The use according to claim 3, characterized in that: The pregnant woman is a pregnant woman suffering from iron deficiency anemia.

5. The use according to claim 3, characterized in that: The adverse pregnancy outcome for pregnant women is an adverse pregnancy outcome caused by iron deficiency anemia during pregnancy.

6. The use according to claim 3, characterized in that: The adverse pregnancy outcome is an adverse pregnancy outcome for the fetus.

7. The use according to claim 6, characterized in that: The adverse pregnancy outcome is fetal growth restriction.

8. The use according to claim 7, characterized in that: The fetal growth restriction is fetal growth restriction caused by decreased fetal weight, shortened fetal length and / or decreased placental weight.

9. The use of cinnamaldehyde in the preparation of drugs for alleviating fetal growth restriction.

10. The use according to claim 9, characterized in that: The fetal growth restriction is fetal growth restriction caused by decreased fetal weight, shortened fetal length and / or decreased placental weight.

Images